Constitutive Gs activation using a single-construct tetracycline-inducible expression system in embryonic stem cells and mice by Hsiao, Edward C et al.
RESEARCH Open Access
Constitutive Gs activation using a single-construct
tetracycline-inducible expression system in
embryonic stem cells and mice
Edward C Hsiao
1,2*, Trieu D Nguyen
1, Jennifer K Ng
1, Mark J Scott
1, Wei Chun Chang
3, Hengameh Zahed
4,5,
Bruce R Conklin
1,6
Abstract
Introduction: The controlled expression of many genes, including G-protein coupled receptors (GPCRs), is
important for delineating gene functions in complex model systems. Binary systems for inducible regulation of
transgene expression are widely used in mice. One system is the tTA/TRE expression system, composed of a
tetracycline-dependent DNA binding factor and a separate tetracycline operon. However, the requirement for two
separate transgenes (one for each tTA or TRE component) makes this system less amenable to models requiring
directed cell targeting, increases the risk of multiple transgene integration sites, and requires extensive screening
for appropriately-functioning clones.
Methods: We developed a single, polycistronic tetracycline-inducible expression platform to control the expression
of multiple cistrons in mammalian cells. This platform has three basic constructs: regulator, responder, and
destination vectors. The modular platform is compatible with both the TetOff (tTA) and TetOn (rtTA) systems. The
modular Gateway recombineering-compatible components facilitate rapidly generating vectors to genetically
modify mammalian cells. We apply this system to use the elongation factor 1a (EF1a) promoter to drive
doxycycline-regulated expression of both the fluorescent marker mCherry and an engineered Gs-coupled GPCR
“Rs1” separated by a 2A ribosomal skip site.
Results: We show that our combined expression construct drives expression of both the mCherry and Rs1
transgenes in a doxycycline-dependent manner. We successfully target the expression construct into the Rosa26
locus of mouse embryonic stem (ES) cells. Rs1 expression in mouse ES cells increases cAMP accumulation via both
basal and ligand-induced Gs mechanisms and is associated with increased embryoid body size. Heterozygous mice
carrying the Rs1 expression construct showed normal growth and weight, and developed small increases in bone
formation that could be observed in the calvaria.
Conclusions: Our results demonstrate the feasibility of a single-vector strategy that combines both the tTA and
TRE tetracycline-regulated components for use in cells and mouse models. Although the EF1a promoter is useful
for driving expression in pluripotent cells, a single copy of the EF1a promoter did not drive high levels of mCherry
and Rs1 expression in the differentiated tissues of adult mice. These findings indicate that promoter selection is an
important factor when developing transgene expression models.
* Correspondence: edward.hsiao@ucsf.edu
1Gladstone Institute of Cardiovascular Disease, 1650 Owens St., San
Francisco, CA 94158, USA
Full list of author information is available at the end of the article
Hsiao et al. Stem Cell Research & Therapy 2011, 2:11
http://stemcellres.com/content/2/2/11
© 2011 Hsiao et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
G-protein coupled receptors (GPCRs) are the largest
family of cell-surface receptors. GPCRs mediate a wide
variety of biological processes and responses to extracel-
lular signals and are the major targets for over 40% of
modern pharmaceuticals [1]. However, the diversity of
the GPCR family, as well as the presence of constitutive
signaling in some GPCRs, poses major challenges for
studying the effects of GPCR signaling in in vitro and
in vivo systems.
Receptors activated solely by synthetic ligands
(RASSLs) provide one method for experimentally
manipulating the timing and activation of G-protein
pathways [2,3]. RASSLs are engineered receptors that no
longer respond to endogenous hormones, but are
activated by synthetic small-molecule drugs. They have
proven valuable for studying the roles of activated
G-protein signaling in complex systems, including cardi-
omyocyte function [4], neurological development and
function [5-7], and bone development [8-11].
Since many GPCRs show both constitutive and ligand-
activated signaling, having temporal and tissue-specific
control of GPCR transgene expression is important for
delineating specific signaling functions. A variety of bin-
ary expression systems are used in genetic model organ-
isms to achieve regulated expression, including the
GAL4/UAS [12] and the tetracycline-regulated (tTA/
TRE) system [13]. The tTA/TRE system uses two sepa-
rate components to regulate spatial and temporal gene
expression: a regulator construct, containing a promoter
to drive tissue-specific expression of either the tetracy-
cline-controlled transactivator (tTA; TetOff) or the
reverse tetracycline-controlled transactivator (rtTA;
TetOn); and a responder construct bearing the minimal
TetO promoter and a tetracycline-responsive element
(TRE) to temporally control expression of the gene of
interest. This system has been shown to control the
expression of “Rs1,” an engineered Gs-coupled GPCR
with high constitutive Gs signaling activity, for regulated
expression in mouse osteoblasts [8-10].
A l t h o u g ht h eb i n a r yt T A / T R Es y s t e mi sp o w e r f u lf o r
generating tissue-specific tetracycline-inducible trans-
genic mouse models, the requirement for two separate
constructs poses significant challenges for using the sys-
tem in cell lines. Various methods are available for
introducing the responder and regulator constructs
independently (for example, by mixing lentiviral con-
structs or sequential transgene introduction). These
methods have significant limitations: the exact ratios of
the responder and regulator plasmids are not fully con-
trolled, the constructs may integrate at multiple sites
(thus increasing the risk of off-target effects), and sepa-
rate drug resistance genes may be needed to ensure that
both constructs are maintained as stable integrants.
To address these challenges and determine if global Gs
signaling affects early mouse development, we developed
a single-vector polycistronic Tet-inducible expression
platform based on a modular construction strategy. This
platform uses three vectors that can be recombined to
form a single Tet-inducible expression vector. In con-
trast to several prior methods for combining the tTA/
TRE components [14-22], our platform is compatible
with both the TetOff (tTA) and TetOn (rtTA) technolo-
gies and is rapidly adaptable for multiple gene delivery
backbones commonly used in eukaryotic cell lines (for
example, lentivirus or Rosa26 targeting).
In this study, we demonstrate the utility of our single-
vector constructs in mouse embryonic stem (ES) cells
and mice. We show that expression of both mCherry
and the Gs-coupled RASSL Rs1 can be tightly controlled
with doxycycline in mouse ES cells. In addition, we
show that a Rosa26 knock-in construct using the EF1a
promoter to drive expression of Rs1 and mCherry is
functional in mice, but that the EF1a promoter does
not drive high expression of the transgenes in all tissues
of adult mice. Finally, our results indicate that low-level
expression of a GPCR with constitutive Gs activity leads
to a mild increase in calvarial bone formation.
Materials and methods
Plasmids
All plasmid constructs used in this study, their Addgene
accession numbers, and maps are summarized in Table
S1 in Additional File 1 and Figures S1A-H in Additional
File 2.
attL1L3 entry vectors
The pEntr2B entry vector (Invitrogen, Carlsbad, CA,
USA) was digested with PstI and XhoI to remove the
attL2 site. Oligonucleotides containing SalI-XhoI-
Bsu36I-NdeI-PacI-EcoRI-NotI flanking the attL3
sequence on the 5’ side and PstI on the 3’ side were
ligated in to create an intermediate plasmid carrying
attL1 and attL3 sites (from pDest R4-R3, Invitrogen).
A LoxP sequence was introduced at the XhoI site, and
the 500-bp chicken b-globin (CBG) HS4 insulator
sequence [23] was introduceda tt h eB s u 3 6 I / N d e Is i t e s .
The tTA and pA sequences were subsequently cloned
into the EcoRI/NotI sites by PCR cloning from
pUHG15-1 [24] to generate pEntL1L3 tTA-2. The EF1a
promoter from pORF9 (Invivogen, San Diego, CA, USA)
was cloned into the PacI site to generate the final entry
vector pEntL1L3 EF1a-tTA-2. The construct was veri-
fied by sequencing.
attR3L2 entry vectors
The pEntr2B entry vector was digested with AflII and
XhoI to remove the attL1 and ccdb genes. Oligos con-
taining the attR3 site flanked by AflII on the 5’ end and
a polylinker (NotI-PacI-Bsu36I-NdeI-XhoI) on the 3’
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intermediate. Using PCR cloning, the TetO-beta globin
intron sequence from pTetO (pUHD10.3) [13,24] was
cloned into the NotI/PacI sites in the reverse orienta-
tion, and a 3’ SbfI site was introduced. The pA sequence
from pDest27 (Invitrogen) was then cloned into the
NotI/SbfI sites, again in reverse orientation. A LoxP site
was introduced into the NdeI/XhoI sites, allowing full
excision of the targeted construct when used together
with the LoxP site in the pEntl1L3 vector. The CBG
core insulator was then cloned into the Bsu36I/NdeI
sites to generate the starting entry vector pEntR3L2
TetO(fl)-2. The construct was fully sequence verified.
The mCherry-P2A-Rs1 RASSL cassette was cloned into
the NotI site to generate pEntR3L2 TetO(sh) mCh-Rs1-
2. The Rs1 was PCR amplified from pUNIV-SIG-
5HTR4D100A [8] and the mCherry was PCR cloned
from pRset-mCherry [25]. The self-cleaving 2A site gen-
erates two separate peptides in equal concentrations
[26,27] via a ribosomal “skip” mechanism just before the
C-terminal end of the 2A peptide [28] and has been
useful for making multicistronic reporters [29]. During
sequencing of the final pEntR3L2 TetO(sh) mCh-Rs1-2
construct (abbreviated pEntR3L2 TetO-mCh-Rs1 in the
remainder of this study), the TetO region was noted to
carry a deletion of two of the 7 tTA binding site repeats.
However, the shortened TetO retained comparable func-
tion to the full-length TetO (designated with “fl” for full
length) in separate in vitro assays (data not shown).
Rosa26 R1R2 destination vector (pRosa26 R1R2 RexNeo)
The Rosa26-1 plasmid [30] [Addgene: 21714] was
digested at the XbaI cloning site and a PCR product
containing the attR1-ccdb-attR2 sequences from
pDest27 and an additional PacI site was introduced. The
Rex-Neo resistance cassette from the aMHC-eGFP-Rex-
Neo lentivirus plasmid [31] was PCR-cloned into the
PacI site to allow for antibiotic selection in eukaryotic
cells with G418. The modified regions were verified by
sequencing.
pcDNA3.2-GWdel CMV destination vector
To create a generic promoter-less destination vector, the
pcDNA3.2/V5-DEST (Invitrogen) plasmid was digested
with SpeI and SacI, filled in using Klenow fragment, and
re-ligated. Sequencing verified that the resulting plasmid
has the majority of the CMV promoter removed.
Generating the combined EF1a-tTA/TetO-mCh-Rs1
expression vectors
The final expression vector for introducing the EF1a-
tTA/TetO-mCh-Rs1 construct into mammalian cells
was generated by LR multisite recombination with LR
Clonase Plus (Invitrogen). In accord with protocols pro-
vided by the manufacturer, the attL1L3 and attR3L2
entry vectors were recombined with attR1R2 destination
vectors (pRosa26 R1R2 RexNeo or pcDNA3.2-
GWdelCMV) to generate the expression vectors Exp-
R26(EF1a-tTA/TetO-mCh-Rs1) and Exp-pcDNA3.2
(EF1a-tTA/TetO-mCh-Rs1). The recombineering junc-
tions within the final expression vectors were verified by
sequencing.
Generating Rosa26-targeted ES cells R26(EF1a-tTA/TetO-
mCh-Rs1)
Feeder-independent mouse ES cells (129/OlaHsd strain,
sub-line E14Tg2A.4) were maintained in normal growth
medium supplemented with murine leukemia inhibiting
factor as described [32]. Exp-R26(EF1a-tTA/TetO-mCh-
Rs1) was linearized with AgeI. The DNA was electropo-
rated into 3 × 10
6 ES cells using a BioRad Gene Pulser
XCell at 800 V, 10 μF, and Tc = 0.3. ES cell cultures
were selected in normal growth medium [32] supple-
mented with 175 ng/ml neomycin (Gibco BRL/Invitro-
gen, Carlsbad, CA, USA) and 1 ng/ml doxycycline
(Sigma Aldrich, St. Louis, MO, USA) for 10 days.
Twenty-nine colonies were identified and expanded, and
colonies were subsequently genotyped by non-radioac-
tive Southern blot (GE RPN3690 kit with CDP-Star)
with a 500-bp probe 5’ to the targeting vector and fol-
lowing the manufacturer’s directions for labeling, hybri-
dization, and detection. This probe was generated by
PCR amplification from a plasmid containing the
Rosa26 5’ region using forward primer ECH141 (5’
TTCGCCCTTTAGGAACAAGA 3’) and reverse primer
ECH142 (5’ TTTTGCCAATTGTTCCTGTG 3’)f r o m
the Rosa26-5’ probe plasmid [30] [Addgene: 21715]. The
R26(EF1a-tTA/TetO-mCh-Rs1) ES cells were deposited
with the MMRRC [MMRRC: 34358].
Transiently transfected HEK-293 cells
HEK-293 cells were maintained in standard growth
medium with 10% FBS. Plasmids were introduced into
cells using Lipofectamine 2000 (Invitrogen), according
to manufacturer’s protocol. Medium was supplemented
with 1 ng/ml doxycycline (a tetracycline analog) (Sigma
Aldrich). Expression of the transgenes was characterized
by fluorescent microscopy and FACS analysis.
FACS analysis of transgene expression
R26(EF1a-tTA/TetO-mCh-Rs1) ES cells cultured in the
presence or absence of doxycycline were treated with 3
mg/ml collagenase I (Worthington Biochemical Corp.,
Lakewood, NJ, USA) for 10 to 20 minutes until the cells
detached from the culture plate. The cells were collected
and passed through a cell strainer before FACS analysis
using the BD LSRII (BD Biosciences, San Jose, CA,
USA) for mCherry expression. FlowJo (TreeStar, Ash-
land, OR, USA) software was used to analyze flow cyto-
metry data.
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Suspension embryoid bodies (EBs) were formed by seed-
ing 3 × 106 ES cells into a 10-cm low-attachment dish
(Corning, Lowell, MA, USA) and allowing the cells to
self-aggregate. Cells were maintained for eight days in
differentiation medium containing 20% FBS [33,34].
Supplements included 10 ng/ml doxycycline or 50 ng/
ml RS67333, as indicated in the experiment figures.
Images of EBs were captured over the entire plate by a
Zeiss Axiovert 200 M microscope and Axiovision soft-
ware. EB size was determined by pixel counting using
ImageJ software [35,36] and analyzed on Excel (Micro-
soft Corp., Seattle, WA, USA).
cAMP accumulation assay
Rs1-expressing cells were seeded in a poly-d-lysine and
laminin-coated 24-well plate at a density of 350,000
cells/well. After 24 hours, the cells were treated with 1
μM drug (serotonin or RS67333) for 10 minutes at 37°
C. The treatment solution was aspirated off and the
cells were lysed. The cell lysates were assayed for cAMP
accumulation using the cAMP HiRange HTRF kit (Cis-
Bio US, Bedford, MA, USA).
Generation of EF1a-tTA/TetO-mCh-Rs1 mice
All transgenic mouse studies were approved by and per-
formed in accordance with the Institutional Animal Care
and Use Committee and the Laboratory Animal Research
Center at the University of California, San Francisco.
Mouse chimeras were generated by the Gladstone Trans-
genic/Gene Targeting Core facility by injection of E14 ES
cells carrying the Exp-R26(EF1a-tTA-mCh-Rs1-TetO
(sh)-2) knock-in construct and backcrossed to the C57Bl/
6 line. Germline transmission was identified by PCR
using the primers ECH103 (5’ TC ATGGAAATCTCC-
GAGGCG 3’) and ECH162 (5’ CGA GGGCTCAG
TTGGGCTGTTT 3’; 490-bp product) to detect the wild-
type R26 allele and ECH137 (5’ ACGTCGA CTGAA
TTGGTTCC 3’) and ECH161 (5’ CCTCTTCCC
CTCGTGATCTGCA 3’; 262 bp product) to detect the
recombined allele. Genotyping was performed with the
REDExtract-N-Amp Tissue PCR kit (Sigma Aldrich) as
directed by the manufacturer. Transgene expression was
suppressed by continuous administration of doxycycline-
impregnated mouse chow (DoxDiet 200 mg/kg; Bio-Serv,
Frenchtown, NJ, USA). Transgene expression was
activated by switching the mice to regular mouse chow
without doxycycline (LabDiet 5053, PMI Nutrition,
St. Louis, MO, USA). Both males and females were ana-
lyzed together in our experiments as no sex-dependent
differences were observed. The ColI(2.3)-tTA and TetO-
Rs1 transgenic mice are as described [8]. The EF1a-tTA/
TetO-mCh-Rs1 mice are deposited with the Mutant
Mouse Regional Resource Center [MMRRC:034320].
RNA expression analysis
Gene expression analysis was performed on RNA isolated
from the selected tissues or from the right humerus of
adult experimental animals, as indicated in the figures.
Bones for each experiment were batch processed by
crushing (multi-sample Bio-Pulverizer, Research Pro-
ducts International, Prospect, IL, USA). All tissues,
including the crushed bone, were homogenized (4.5 mm
Tissue Tearor, Research Products International) in
RNAStat-60 (Iso-Tex Diagnostics, Friendswood, TX,
USA) and total RNA was isolated according to the manu-
facturer’s instructions. cDNA was generated using the
SuperScript III First Strand Synthesis kit (Invitrogen)
as directed by the manufacturer. Expression was
assayed using SybrGreen or Taqman primers for Rs1
and GAPDH as described [8,10]; SybrGreen primers for
tTA (Forward: 5’ CGCCCAGAAGCTAGGTGTAG 3’;
Reverse 5’ CCCCTTCTAAAGGGCAAAAG 3’); and
SybrGreen primers for mCherry (Forward: 5’ CCTGT
CCCCTCAGTTCATGT 3’; Reverse: 5’ GCTTCAAG
TAGTCGGGGATG 3’). Taqman probe sets used
for expression analysis for apoptosis, pluripotency,
and differentiation markers are as follows: Bad
(Mm00432042_m1), Ccnb3 (Mm00805476_m1), Mcl1
(Mm01257352_g1), Oct3/4 (Mm00658129_gH) and Sox2
(Mm00488369_s1), Foxa2 (Mm01976556_s1), Nestin
(Mm00450205_m1), Nkx2.5 (Mm00657783_m1), ANF
(Mm00431717-m1), MyoD (Mm00440387_m1), and
Sox17 (Mm00488363_m1). All samples were assayed in
technical triplicates, and expression levels were normal-
ized to GAPDH. All qPCR reactions were run on an
Applied Biosystems (Foster City, CA, USA) 7900 HT
real-time thermocycler.
Bone densitometry
Mice identified for dual-energy x-ray absorptiometry
(DEXA) to measure whole-body areal bone mineral den-
sity (BMD) were anesthetized with inhaled isofluorane
(1.5 to 2% in oxygen) and scanned on a GE Lunar Pixi-
mus2 (Waukesha, WI, USA) as described [8].
Results
Assembly of single-vector poly-cistronic Tet-regulated
expression vectors
To create a single-vector Tet-regulated expression con-
struct, we used a modular cloning strategy employing
the Gateway recombineering system [37] with standar-
dized entry vector plasmids to assemble the tetracycline-
regulated components into different destination vector
backbones (Figure 1A). Briefly, the regulator vector,
containing attL1 and attL3 sites, carries the promoter
(that is, the ubiquitous promoter EF1a [38]) used to
drive expression of either the tTA or rtTA regulator.
The responder vector, containing attL2 and attR3 sites,
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linked to the gene of interest. The destination vector
contains the recipient attR1 and attR2 sites, as well as a
selectable marker, and serves as the final backbone for
expressing the transgenes in mammalian cells. Multiple
Gateway destination vectors based on standard expres-
sion plasmids, lentiviral expression vectors, and knock-
i nc o n s t r u c t sa r en o wg e n e r a l l ya v a i l a b l e( e . g . ,f r o m
Invitrogen or Addgene).
We combined the regulator, responder, and destina-
tion vectors by Gateway recombineering to create the
final single-vector Tet-inducible expression constructs.
The regulator and responder cassettes were designed
to lie in opposite orientations with the polyA tails
nearest each other, thus preventing cross-activation
and transcriptional read-through. Additional spacer
DNA was placed between the opposing pA sequences
to minimize the risk of steric interference of the RNA
polymerases. The unidirectional three-way Gateway
recombination strategy ensures that the regulator and
responder cassettes are always positioned in the proper
orientation. In addition, insulator sequences from the
chicken b-globin gene flank both sides of the construct
to prevent inadvertent read-through into the expres-
sion cassettes. Finally, we placed flanking LoxP sites
around the construct to allow for Cre-mediated
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Figure 1 A single-vector tetracycline construct allows doxycycline-regulated expression. (A) Overview showing the regulator plasmid
containing the EF1a-tTA cassette (pEntL1L3-EF1a-tTA, left) and the responder plasmid containing the TetO-mCh-Rs1 cassette (pEntR3L2 TetO-
mCh-Rs1, right). The mCherry and Rs1 cistrons are separated by a P2A ribosomal skip sequence to allow simultaneous expression of both
peptides. The entry plasmids were recombined using Gateway technology into the desired destination vector containing the AttR1 and AttR2
Gateway sites. The TetO and EF1a-tTA portions are in opposite orientation (indicated by upside-down text) to minimize steric hindrance
between the two promoters, as well as potential cross-activation of the TetO by the EF1a promoter. In addition, flanking insulator sequences are
included to minimize any read-through activation of the constructs by surrounding promoters (such as Rosa26) that may lead to “leakiness” or
steric interference from endogenous promoter activity. (B, C) HEK-293 cells carrying the Exp-pcDNA3.2(EF1a-tTA/TetO-mCh-Rs1) expression
cassette and cultured in doxycycline (suppressed expression) or in the absence of doxycycline (transgene expression allowed) demonstrate
doxycycline-dependent mCherry expression. (D) Schematic of targeted Rosa26 locus and Southern screening strategy. The Rosa26 locus in E14
ES cells was targeted by homologous recombination with the Exp-R26(EF1a-tTA/TetO-mCh-Rs1) construct. Regions in hatch marks indicate the 5’
and 3’ homology regions of the targeting vector and the endogenous Rosa26 locus (abbreviated R26 in the figure). The location of the 5’
recombination Southern probe and HindIII restriction sites are indicated. (E) Southern blots of genomic DNA digested with HindIII and probed as
in (D). Heterozygous ES cells at the Rosa26 locus are indicated by the two bands.
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option of a negative control by excision for epigenetic
and integration effects.
Doxycycline-inducible transgenes in mammalian cells
To test the functionality of our platform, we created
the expression construct Exp-pcDNA3.2(EF1a-tTA/
TetO-mCh-Rs1) to express the Gs-coupled RASSL,
“Rs1,” ubiquitously. The Rs1 and mCherry cistrons are
separated by a P2A ribosomal skip sequence, which
allows genes to be expressed simultaneously from the
same promoter [28]. The 2A sequences have also been
used to express peptides in equimolar ratios [26,27].
For ubiquitous tTA transactivator expression, we con-
structed a regulator vector where the EF1a promoter
drives tTA. Previous studies indicate that the EF1a
promoter could direct expression of reporter genes in
a variety of cell types and tissues at high levels [38-40].
For the destination vector, we used a modified expres-
sion plasmid with the majority of the CMV promoter
removed (pcDNA3.2GW-delCMV).
The Exp-pcDNA3.2(EF1a-tTA/TetO-mCh-Rs1) con-
struct was transiently transfected into HEK-293 cells and
cultured in either regular medium without doxycycline
or in medium with 10 ng/ml doxycycline (Figure 1B,C).
Cells cultured in the presence of doxycycline, thus sup-
pressing the transactivator activity, showed no mCherry
expression after 24 hours (Figure 1B). In contrast, cells
cultured in the absence of doxycycline showed robust
mCherry expression (Figure 1C), indicating doxycycline-
dependent suppression of transgene expression from our
expression construct.
Targeting the combined mCherry and Rs1 expression
construct to the Rosa26 locus
To determine if activation of the Gs signaling pathway
affects embryonic stem cell growth, we created a Gate-
way-modified destination vector to target the Rosa26
locus (pRosa26 R1R2 RexNeo) for expression of the
combined EF1a-tTA and TetO-mCh-Rs1 components.
Using Gateway recombineering, we combined the
pEntL1L3 EF1a-tTA regulator, pEntR3L2 TetO-
mCh-Rs1 responder, and the Rosa26 R1R2 RexNeo
destination vectors to generate the Exp-R26(EF1a-
tTA/TetO-mCh-Rs1) knock-in expression vector
(Figure 1D). Site-specific introduction of the expres-
sion cassette into the transcriptionally-permissive
Rosa26 locus was performed by gene targeting into
E14Tg2A.4 mouse ES cells. Positive clones were identi-
fied after G418 selection. Twenty-nine colonies were
screened by Southern blot. One ES cell colony (line
A6) was identified carrying the correct Rosa26 modifi-
cation, designated R26(EF1a-tTA/TetO-mCh-Rs1)
(Figure 1E), and used for subsequent studies.
Rs1 activation induces cAMP accumulation in mouse
ES cells
Analysis of the R26(EF1a-tTA/TetO-mCh-Rs1) mouse
ES cell line demonstrated that both the Rs1 and
mCherry cistrons were expressed in a doxycycline-
dependent manner. ES cells cultured without doxycy-
cline for 48 hours showed brighter labeling with
mCherry than ES cells cultured in 10 ng/ml doxycycline.
Furthermore, although a low level of mCherry expres-
sion was detected when the cells were cultured in doxy-
cycline as compared to unlabeled wildtype ES cells, the
percentage of mCherry-positive cells markedly increased
when doxycycline was removed (Figure 2A).
Both constitutive and ligand-induced activities of the
Rs1 RASSL were preserved in the presence of the P2A
ribosomal skip sequence. We previously showed that the
Rs1 RASSL is Gs-coupled and can induce an intracellu-
lar increase in cAMP levels by both basal and ligand-
induced mechanisms [8,41]. In the R26(EF1a-tTA/
TetO-mCh-Rs1) ES cells, cAMP accumulation was mini-
mally increased in mock-treated cells expressing Rs1 as
compared to wildtype or doxycycline-suppressed con-
trols (Figure 2B). cAMP levels were further increased in
the Rs1-expressing cells cultured with the serotonin
receptor agonist RS67333 (Figure 2B) [8,41].
These data show that the R26(EF1a-tTA/TetO-
mCh-Rs1) single vector Tet-off polycistronic expression
construct in ES cells can be tightly controlled with dox-
ycycline, that both the Rs1 and mCherry cistrons can be
expressed from a single locus when separated by a P2A
sequence, and that both basal and ligand-mediated
increases in cAMP can be induced by the Rs1 RASSL in
ES cells.
Rs1 activation leads to larger embryoid bodies
To determine the effect of higher cAMP levels during
the differentiation of ES cells, we cultured the R26
(EF1a-tTA/TetO-mCh-Rs1) ES cells for 48 hours either
with or without doxycycline and then formed EBs using
suspension culture conditions. At Day 4 of differentia-
tion, we divided the EBs cultured without doxycycline
into two groups (Figure 2C). One group was treated
with the Rs1 agonist RS67333, and the other remained
untreated. EB size was analyzed on Day 8. We detected
an increase in EB size in both the Rs1-expressing and
RS67333-treated groups (Figure 2D, E). R26(EF1a-tTA/
TetO-mCh-Rs1) EBs continually cultured with doxycy-
cline to suppress Rs1 expression were the same size as
EBs derived from wildtype E14 ES cells. Rs1 mRNA
levels were not significantly different between EBs cul-
tured with or without RS67333 (data not shown).
R26(EF1a-tTA/TetO-mCh-Rs1) ES cells expressing Rs1
and grown without doxycycline appeared to proliferate
similarly to cells grown with doxycycline. Additionally, the
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levels of apoptosis or proliferation markers (Bad, Mcl1,
and Ccnb3) [42] as detected by qPCR. To test whether
Rs1 expression may affect cellular differentiation, and thus
cell size, we used qPCR to assess the mRNA levels of mar-
kers of pluripotency (Oct3/4 and Sox2) and mRNA mar-
kers for all three germ layers (Foxa2, Nestin, Nkx2.5, ANF,
MyoD, and Sox17) [43]. Rs1-expressing ES cells cultured
with or without doxycycline showed no differences in
mRNA levels for these genes (data not shown).
These results demonstrate that Gs signaling during EB
formation can increase EB size, but that this increase in
size is not a result of detectable changes in cell prolif-
eration, apoptosis, or cellular differentiation.
EF1a-tTA/TetO-mCh-Rs1 mice
Since Rs1 expression in mouse ES cells increased EB size,
we sought to determine if global constitutive Gs signaling
could affect tissue development of a whole mouse. ES cells
carrying the R26(EF1a-tTA/TetO-mCh-Rs1) construct
were injected into mouse blastocysts. Fourteen high-
percentage chimeras were identified, and two lines (Line A
and Line B) were backcrossed onto the C57Bl/6 back-
ground. Mice were maintained and mated on doxycycline-
containing chow to suppress transgene expression and
minimize any risk of embryonic lethality, as has been
hypothesized to occur in diseases with activated Gs signal-
ing during embryogenesis such as McCune-Albright Syn-
drome [44]. R26(EF1a-tTA/TetO-mCh-Rs1) mice raised
off of doxycycline to allow global expression of Rs1 from
gestation were viable and showed no detectable weight,
length, or pigmentation changes. Despite the previous
reports of ubiquitous EF1a promoter activity, expression
analysis on four-week-old mice raised on and off doxycy-
cline showed that Rs1 mRNA levels were generally very
low and near the detection limit of our qPCR assay. Sur-
prisingly, only whole bone showed an induction of Rs1
expression in mice raised off of doxycycline (Figure 3). In
contrast to the induction of Rs1 expression in R26(EF1a-
tTA/TetO-mCh-Rs1) mouse ES cells, these findings indi-
cate that the R26(EF1a-tTA/TetO-mCh-Rs1) mice had
poor induction of Rs1 expression in most tissues in the
absence of doxycycline.
R26(EF1a-tTA/TetO-mCh-Rs1) test crosses
Since the R26(EF1a-tTA/TetO-mCh-Rs1) mice showed
only minimal Rs1 expression in vivo,w es o u g h tt ot e s t
whether the tTA regulator portion, the TetO responder
portion, or both may be non-functional. Since ColI(2.3)-
tTA/TetO-Rs1 mice have a dramatic and easily-detectable
bone phenotype [8], we crossed the mice carrying the
TetO-Rs1 and R26(EF1a-tTA/TetO-mCh-Rs1) transgenes
to test the EF1a-tTA portion and crossed the mice carry-
ing the ColI(2.3)-tTA and R26(EF1a-tTA/TetO-mCh-Rs1)
transgenes to test the function of the TetO-mCh-Rs1
portion in vivo.
If the EF1a-tTA portion of the R26(EF1a-tTA/TetO-
mCh-Rs1) construct was capable of regulating TetO
activity in vivo, we would predict that the TetO-Rs1 x
R26(EF1a-tTA/TetO-mCh-Rs1) mice would show
symptoms reminiscent of McCune-Albright syndrome
including embryonic lethality, fibrous dysplasia of the
bone, short stature, hormonal disturbances, and skin pig-
mentation defects [45]. However, the TetO-Rs1 x R26
(EF1a-tTA/TetO-mCh-Rs1) mice bred and maintained
off of doxycycline showed no embryonic lethality (TetO-
Rs1 single transgenic = 17; R26(EF1a-tTA/TetO-mCh-
Rs1) single transgenic = 16; TetO-Rs1 x R26(EF1a-tTA/
TetO-mCh-Rs1) double transgenic = 9; wildtype = 11.
Total = 53 mice; Chi-squared P = 0.33) and were pheno-
typically indistinguishable from their littermates.
To determine if the TetO-mCh-Rs1 responder portion
of the construct containing a P2A ribosomal skip
sequence was functional, we generated ColI(2.3)-tTA x
R26(EF1a-tTA/TetO-mCh-Rs1) mice. At nine weeks of
age, the double mutants showed a significant increase in
bone mineral density (Figure 4A) that was comparable
to our published results in the ColI(2.3)-tTA/TetO-Rs1
mice [8]. Further analysis by qPCR of RNA isolated
from whole femurs showed that Rs1, mCherry, and tTA
expression could be easily detected in the double
mutant mice and at relatively comparable levels, but
Rs1, mCherry, and tTA expression were not readily
detectable in the bones of R26(EF1a-tTA/TetO-mCh-
Rs1) single mutant mice (Figure 4B). Images of calvaria
from the double mutant mice ColI(2.3)-tTA x R26
(EF1a-tTA/TetO-mCh-Rs1) show that red fluorescence
from the mCherry could be visualized, but not in the
Figure 3 Rs1 expression in R26(EF1a-tTA/TetO-mCh-Rs1) mice
show significant variability and degrees of induction among
different tissues. Rs1 expression was allowed (off doxy) or
suppressed (on doxy) in mice for four weeks starting from gestation.
mRNA levels were assessed by qPCR for Rs1. Representative mice
are shown. Error bars represent average +/- 1 SD of technical
triplicates.
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mutant or control mice (Figure 4C). However, a small
amount of increased bone formation could be detected
i nt h ec a l v a r i ao fR 2 6 ( E F 1 a-tTA/TetO-mCh-Rs1) mice
as indicated by the increased opacity in the frontal and
parietal bones (Figure 4C), consistent with the low level
of Rs1 expression previously observed (Figure 3).
These findings show that a single copy of the R26
(EF1a-tTA/TetO-mCh-Rs1) construct can drive a low
level of Rs1 expression in vivo in some tissues, and that
the low level of Rs1 expression is due to low activity of
the EF1a-tTA portion of the combined transgene. Our
results also show that the Rs1 and mCherry cistrons can
be expressed from a single locus when separated by a
P2A sequence, and that the Rs1 receptor expressed in
this manner retains biological activity in vivo.
Discussion
We created a modular system that uses Gateway recom-
bineering technology to combine the binarytetracycline-
regulated expression components into a single vector. By
using a targeting vector with a known genomic insertion
site (Rosa26), we could introduce all of the components
needed for tetracycline-regulated expression into a well-
characterized and transcriptionally-active locus. This
strategy allows us to use the same cell line for both the
Figure 4 A single copy of the EF1a-tTA regulator region weakly drives expression of a TetO transgene in mice. (A) Areal bone mineral
density by DEXA of nine-week-old mice shows that the ColI(2.3)-tTA x R26(EF1a-tTA/TetO-mCh-Rs1) mice have increased bone mass. N = 9 WT,
5 R26(EF1a-tTA/TetO-mCh-Rs1), and 9 ColI(2.3)-tTA x R26(EF1a-tTA/TetO-mCh-Rs1) mice. ***, P < 0.0001 vs. wildtype (WT). (B) RNA expression
levels of Rs1, tTA, and mCherry in the humeri of nine-week-old ColI(2.3)-tTA x R26(EF1a-tTA/TetO-mCh-Rs1) and littermate controls, showing
highest expression in the double-mutant mice. Error bars represent means of technical qPCR triplicates +/- 1 SD. (C) Fluorescence images of
calviaria from representative 16-week-old littermate mice showing strongest mCherry expression [assessed in the Texas Red (TxR) channel] in ColI
(2.3)-tTA x R26(EF1a-tTA/TetO-mCh-Rs1) but not wildtype littermates. Although mCherry was not clearly detected in the R26(EF1a-tTA/TetO-
mCh-Rs1) calvaria, subtle increases in the mineralization of the skull bones (white patches, as indicated by the yellow arrow) are present
indicating functional responses to Rs1. The level of bone formation is lower than that seen in the ColI(2.3)-tTA x R26(EF1a-tTA/TetO-mCh-Rs1)
(green arrow), where additional activation of the Rs1 transgene is achieved by adding osteoblast-specific expression of the tTA element.
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Rs1 expression suppressed) conditions, thus significantly
decreasing the problem of clonal variability.
Although a variety of methods for combining the tetra-
cycline-inducible expression components into a single
vector have been described [14-22,46,47], our modular
system has the added advantage of facilitating the rapid
interchange of the expression components for tetracy-
cline-induced expression as well as the choice of viral
and non-viral delivery backbones. We easily inserted the
expression cassettes into two final destination vectors,
including a new Gateway-enabled construct for targeting
into the mouse Rosa26 locus. We then were able to inte-
grate the combined tTA-TetO construct into the Rosa26
locus of pluripotent mouse cells in a single targeting step.
Our expression strategy also took advantage of a P2A
ribosomal skip site to co-express the engineered GPCR
Rs1 and the fluorescent marker mCherry. The P2A
sequence has been used in a variety of systems to gener-
ate independent polypeptides from a single RNA tran-
script [27-29,48]. In our experiments, combining the
mCherry and Rs1 cistrons together allowed us to visua-
lize the expression of mCherry and Rs1 and assess the
effect of Rs1-induced Gs signaling in both ES cell differ-
entiation and mice. Our results indicate that the 2A
strategy produces functional membrane-bound receptors
and reporter proteins from a single RNA transcript.
This strategy will be useful for expressing other GPCRs
since it does not require the addition of a large fusion
protein domain to the receptor.
In our study, expression of Rs1 and activation of Gs sig-
naling in mouse ES cells induced larger EB size. Although
Gs-induced cellular proliferation by cholera toxin can
increase EB size [49], our results indicated no detectable
increase in cellular proliferation, decrease in apoptosis, or
change in ES cell differentiation. We were unable to defi-
nitively assess whether a change in cell size could be con-
tributing to the increased EB size; however, the difference
in observed ES cell proliferation may be a result of lower
Gs activation from the weak EF1a promoter activity in
our system, lower expression of Rs1 in the ES-cell derived
differentiated tissues (as indicated by our mouse results),
or differences in how cholera toxin or GPCRs activate
the Gs or non-cannonical GPCR signaling pathways.
Although a single copy of the EF1a promoter could
drive doxycycline-dependent expression of our construct
in ES cells, it was insufficient to drive high expression of
the transgenes in differentiated mouse tissues. Our study
examined a limited number of founder mice and did not
assess whether EF1a-tTA expression varies between foun-
der lines. However, several other reasons could result in
low levels of tTA expression: the EF1a promoter may not
function as robustly in differentiated tissues as in pluripo-
tent cells; the flanking insulator sequences could result in
transgene silencing; or the reduced number of TetO
repeats in our constructs results in a lower sensitivity to
tTA activation. The latter two possibilities are less likely
since our results from the mouse crosses indicate that the
TetO-mCh-Rs1 portion of the transgene can respond to a
separate transgene expressing tTA from the ColI(2.3)
promoter, suggesting that the R26(EF1a-tTA/TetO-mCh-
Rs1)-targeted locus is not silenced. In addition, prior
studies show that constructs with as few as two TetO
repeats can be induced by tTA [50]. Finally, while we can-
not exclude that the parallel positioning of the EF1a-tTA
construct with the endogenous Rosa26 promoter may
cause transcriptional interference as previously reported
for the CMV promoter [51], this should have been mini-
mized by the use of a 5’ insulator sequence.
The observed low levels of Rs1 expression in mouse
tissues likely accounts for the absence of embryonic
lethality and other pathology we would have expected if
our model mimicked McCune-Albright syndrome [44].
In addition, the differential activity of the EF1a promo-
ter, or different susceptibility of certain tissues to Gs sig-
naling, may be contributing to the heterogeneity of the
Rs1 expression we observed in our R26(EF1a-tTA/
TetO-mCh-Rs1) mice. Increasing the expression of the
tTA transactivator by using an alternative ubiquitous
promoter, such as the CMV-b actin (CAG) promoter
[52], may allow more robust expression of Rs1 and
increased activation of the Gs signaling pathway.
We believe that the modularly-designed single-vector tet
system presented here provides an ideal system for the tis-
sue specific expression of tTA or rtTA as well as the con-
trolled expression of a transgene from the tetracycline
response element. This system could be used for a variety
of genetic studies where a single cassette is advantageous.
Having both components of the tet-inducible system in
the same cassette could facilitate the genetic modification
of ES and induced pluripotent stem cells for regulatory
studies as well as for making engineered tissues.
To facilitate these applications, we generated a series of
improved vectors (Table S2 in Additional File 3 and
Figures S2A-F in Additional File 4). We created a new
Rosa26 targeting vector that contains the yeast PI-SceI
homing sequence (pR26 R1R2 RexNeo PI-SceI) to simplify
linearization of large constructs. We also created pEntL1L3
and pEntR3L2 plasmids without the insulator sequences
and adapter plasmids containing only a multiple cloning
sequence (pEntL1L3-MCS and pEntR3L2-MCS) to allow
use in lentiviral expression constructs (that is, to generate
independent tet-regulator and -responder expression con-
structs in a Gateway-compatible lentivirus backbone such
as pLenti6 (Invitrogen)). We believe that these constructs
will help advance the generation of new inducible expres-
sion models. In addition, these constructs are compatible
with new technologies such as transposon-mediated gene
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as a single cassette and can be easily mobilized into or
excised from the genome [53], as well as newer versions of
the tet regulatory components such as Ptet [54].
Conclusions
The modular system described here allows for rapid gen-
eration of tetracycline-regulated expression constructs for
gene expression studies in tissue culture, ES cells, and
mice. The modular design allows rapid introduction of dif-
ferent combinations of promoters and expressed trans-
genes. The 2A site can also be used to combine a reporter
with an effector gene into a single cistron and is functional
even for membrane-bound receptors, such as GPCRs.
Finally, a single copy of the EF1a promoter was sufficient
to induce transgene expression in mouse ES cells but did
not result in high expression in the differentiated tissues
of a whole mouse. These findings indicate that the specific
choice of the promoter is an important consideration for
driving high expression of the transgenes and that promo-
ters validated for use in tissue culture models may have
different functional characteristics when used in vivo.W e
believe that our modular system for introducing the tetra-
cycline-inducible expression components will facilitate
further development of new types of regulated expression
constructs for use in a wide variety of cell types, including
human ES and induced pluripotent stem cells.
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